Browse > Article

Pharmacokinetics and Bioequivalence of Haloperidol Tablet by Liquid Chromatographic Mass Spectrometry with Electrospray Ionization  

Yun Min-Hyuk (College of Pharmacy, Chungnam National University)
Kwon Jun-Tack (College of Medicine, Soonchunhyang University)
Kwon Kwang-il (College of Pharmacy, Chungnam National University)
Publication Information
Archives of Pharmacal Research / v.28, no.4, 2005 , pp. 488-492 More about this Journal
Abstract
The purpose of this study is to investigate the bioequivalence of two haloperidol 5 mg tablets, Myung In haloperidol (Myung In Pharm. Co., Ltd., test drug) and $Peridol^{R}$(Whanin Pharm. Co., Ltd., reference drug), and also to estimate the pharmacokinetic parameters of haloperidol in Korean volunteers. The bioavailability and pharmacokinetics of haloperidol tablets were examined on 24 healthy volunteers who received a single oral dose of each preparation in the fasting state in a randomized balanced 2 way crossover design. After an oral dosing, blood samples were collected for a period of 60 h. Plasma concentrations of haloperidol were determined using a liquid chromatographic electrospray mass spectrometric (LC-MS) method. The pharmacokinetic parameters were calculated with noncompartmental pharmacokinetic analysis. The geometric means of $AUC_{0-60h} and C_{max}$ between test and reference formulations were $17.21\pm8.26 ng\cdot/mL vs 17.31\pm13.24 ng\cdot/mL and 0.87\pm0.74 ng/mL vs 0.85\pm0.62 ng/mL$. respectively. The $90\%$ confidence intervals of mean difference of logarithmic transformed $AUC_{0-60h} and C_{max} were log0.9677{\sim}log1.1201 and log0.8208{\sim}log1.1981$, respectively. It shows that the bioavailability of test drug is equivalent with that of reference drug. The geometric means of other pharmacokinetic parameters ($AUC_{inf}. t_{1/2}, V_{d}/F, and CL/F$) between test drug and reference drug were $21.75\pm8.50 ng{\cdot}h/mL vs 21.77\pm15.63 ng{\cdot}h/mL, 29.87\pm8.25 h vs 29.60\pm7.56 h, 11.51\pm5.45 L vs 12.90\pm6.12 L and 0.26\pm0.09 L/h vs 0.31\pm0.17 L/h$, respectively. These observations indicate that the two formulation for haloperidol was bioequivalent and, thus, may be clinically interchangeable.
Keywords
Haloperidol; LC-MS; Pharmacokinetic; Bioequivalence; Bioavailability;
Citations & Related Records

Times Cited By Web Of Science : 0  (Related Records In Web of Science)
Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Forsman, A. and Ohman, R., Studies on serum protein binding of haloperidol. Curr. Ther. Res. Clin. Exp., 21, 245-255 (1977)
2 Lacy C., Drug Information Handbook, 8th ed. APHA. 988-989 (2000-2001)
3 Hoja, H., Marquet, P., Verneuil, B., Lotfi, H., Dupuy, J. L., Penicaut, B., and Lachatre, G., Determination of haloperidol and its reduced metabolite in human plasma by liquid chromatography-mass spectrometry with electrospray ionization. J. Chromatography B, 688, 275-280 (1997)   DOI   ScienceOn
4 Ser, F. S., Veljkovie, M., Lazovie, M., and Tomie-Pavlovie, I., Delusions of parasitosis-combined therapy with clomipramine and haloperidol. Journal of the European Academy of Dermatology and Venereology, 9, S237 (1997)   DOI   ScienceOn
5 McEvoy, G. K., AHFS Drug Information, 2128-2129 (2002)
6 Arinobu, T., Hattori, H., Iwai, M., Ishii, A., Kumazawa, T., Suzuki, O., and Seno, H., Liquid chromatographic–mass spectrometric determination of haloperidol and its metabolites in human plasma and urine. J. Chromatography B, 776, 107-113(776) (2002)   DOI   ScienceOn
7 Altamura, A. C., Relapse prevention with neuroleptics in schizophrenia: The role of their bioavailability and pharmacodynamic profile. European Neuropsychopharmacology, 6, S4 (1996)   DOI   ScienceOn
8 Grohmann, R., Koch, R., and Schmidt, L. G., Extrapyramidal symptoms in neuroleptic recipients. Agents Actions Suppl., 29, 71-82 (1990)   DOI   ScienceOn
9 Someya, T., Shibasaki, M., Noguchi, T., Takahashi, S., and Inaba, T., Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction. J. Clin. Psychopharmacol, 12, 169-174 (1992)
10 Casey, D. E. and Keepers, G. A., Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. Psychopharmacol, 5, 74-93 (1998)
11 Walter, S., Bauer, S., Roots, I., and Brockmoller, J., Quantification of the antipsychotics flupentixol and haloperidol in human serum by high-performance liquid chromatography with ultraviolet detection. J. Chromatography B, 720, 211-237 (1998)   DOI   ScienceOn